This is a transformative readout for CYTK, the first positive Phase 3 trial in nHCM with no approved therapies. Expect significant upside at open. Key catalysts ahead: FDA submission timing (likely H2 2026), pricing/reimbursement for expanded indication, and potential partnership or M&A interest given the now de-risked pipeline. Monitor the investor call on May 5 at 8:00 AM ET for regulatory timeline details.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $77.09entry
- T+1 · 7mo ago −2.92%α −4.30% · $74.84
- T+5 · 6mo ago −2.96%α −4.94% · $74.81
- T+20 · 6mo ago −8.02%α −12.97% · $70.91
- T+60 · 4mo ago +4.32%α +1.58% · $80.42
Price Chart
How similar events traded
Executive Summary
Cytokinetics announced positive topline results from the ACACIA-HCM Phase 3 trial of aficamten in non-obstructive HCM, meeting both dual primary endpoints with statistically significant improvements in KCCQ-CSS (p=0.021) and pVO2 (p=0.003) vs placebo at Week 36. This is a major catalyst as there are currently no approved therapies for nHCM, potentially expanding aficamten's addressable market by ~50% (half of all HCM patients).
Key Facts
- ACACIA-HCM met dual primary endpoints: KCCQ-CSS improvement of 3.0 points (p=0.021) and pVO2 improvement of 0.67 mL/kg/min (p=0.003) vs placebo at Week 36
- Statistically significant improvements (p<0.001) in key secondary endpoints: NYHA class, composite z-score of VE/VCO2 and pVO2, and NT-proBNP
- No new safety signals; LVEF <50% occurred in 10% of aficamten vs 1% placebo patients, with 2 serious heart failure adverse events in aficamten arm
- Aficamten (MYQORZO) already approved in U.S., EU, and China for obstructive HCM; this trial targets the ~50% of HCM patients with non-obstructive disease who have no approved therapies
- Company plans to discuss results with FDA and other regulatory authorities for potential label expansion
Financial Impact
Potential to double aficamten's addressable patient population from ~150,000 diagnosed oHCM patients to ~300,000 diagnosed HCM patients in the U.S., with an estimated 400,000-800,000 undiagnosed patients
Risk Factors
- Safety signal: 10% LVEF <50% and 2 serious heart failure events on aficamten may prompt FDA scrutiny despite no new safety signals
- Regulatory risk: FDA could require additional data or limit label to specific nHCM subpopulations
- Competition: Bristol Myers Squibb's mavacamten (Camzyos) is approved for oHCM but not nHCM; could potentially pursue nHCM indication
- Commercial execution risk: Expanding from oHCM to nHCM requires new physician education and patient identification
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287549 |
Track record
46 reports on CYTK
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $56.13 +4.41% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $56.13 +0.00% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $56.13 +1.04% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $56.13 −11.75% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $56.13 −9.51% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers